The thalamus is considered the 'central forum' of the brain where most principal connections diverge. Harnessing this extensive network through neuromodulation has traditionally addressed numerous difficult-to-treat movement disorders such as essential tremor and Parkinson's disease. The therapeutic potential of stimulating this phylogenetically ancient brain structure for other neurological disorders has gained considerable attention since the turn of the 21st century. Even if not stimulated directly, biomarkers, or neural signatures from the thalamus are increasingly being used to assess the therapeutic success of disparate types of neuromodulation technologies. This increased clinical utilization raises the question: Do 'all roads' eventually lead to the thalamus for neuromodulation?
Along with furthering our understanding of thalamic neuromodulation for movement disorders, we are interested in the investigation of its burgeoning use for disorders such as drug-resistant epilepsy and Tourette syndrome. Furthermore, biomarkers measured from the thalamus to gauge the therapeutic effect of central or peripheral neuromodulation is also of interest. Findings from this Research Topic will further contribute to our knowledge of this timely question in neurology.
We welcome contributions that address the use of central or peripheral nervous system neuromodulation, connectional characterization, electrophysiological, and/or neuroimaging methodologies in humans or animal disease models. These specifically include, but are not limited to the following themes:
- Molecular and cellular profiling
- Diffusion tensor imaging
- In vitro and in vivo electrophysiology
- Functional and resting-state magnetic resonance imaging (MRI)
- MRI guided-focused ultrasound
- Deep brain stimulation
- Open- and Closed-loop neurostimulation
- Transcutaneous cranial nerve stimulation
- Transcranial magnetic or direct current stimulation
- Computational modeling
G.D.R. Watson is working as a Medical Science Liaison for the company LIVANOVA.
The thalamus is considered the 'central forum' of the brain where most principal connections diverge. Harnessing this extensive network through neuromodulation has traditionally addressed numerous difficult-to-treat movement disorders such as essential tremor and Parkinson's disease. The therapeutic potential of stimulating this phylogenetically ancient brain structure for other neurological disorders has gained considerable attention since the turn of the 21st century. Even if not stimulated directly, biomarkers, or neural signatures from the thalamus are increasingly being used to assess the therapeutic success of disparate types of neuromodulation technologies. This increased clinical utilization raises the question: Do 'all roads' eventually lead to the thalamus for neuromodulation?
Along with furthering our understanding of thalamic neuromodulation for movement disorders, we are interested in the investigation of its burgeoning use for disorders such as drug-resistant epilepsy and Tourette syndrome. Furthermore, biomarkers measured from the thalamus to gauge the therapeutic effect of central or peripheral neuromodulation is also of interest. Findings from this Research Topic will further contribute to our knowledge of this timely question in neurology.
We welcome contributions that address the use of central or peripheral nervous system neuromodulation, connectional characterization, electrophysiological, and/or neuroimaging methodologies in humans or animal disease models. These specifically include, but are not limited to the following themes:
- Molecular and cellular profiling
- Diffusion tensor imaging
- In vitro and in vivo electrophysiology
- Functional and resting-state magnetic resonance imaging (MRI)
- MRI guided-focused ultrasound
- Deep brain stimulation
- Open- and Closed-loop neurostimulation
- Transcutaneous cranial nerve stimulation
- Transcranial magnetic or direct current stimulation
- Computational modeling
G.D.R. Watson is working as a Medical Science Liaison for the company LIVANOVA.